CAJ | 학술논문

肿瘤坏死因子相关凋亡诱导配体(TRAIL)能与含有死亡域的死亡受体DR4、DR5相结合,诱导多种肿瘤细胞发生凋亡而对正常细胞无明显毒性.但肿瘤细胞对TRAIL的耐受限制了其广泛应用于临床.受体与配体的结合是凋亡信号启动的起始及关键环节,因此肿瘤细胞发生TRAIL耐受的机制与受体的表达、定位、分布、功能等密切相关.联合其他治疗手段针对受体靶点,实现个体化治疗,有望最终克服肿瘤细胞的TRAIL耐受.
종류배사인자상관조망유도배체(TRAIL)능여함유사망역적사망수체DR4、DR5상결합,유도다충종류세포발생조망이대정상세포무명현독성.단종류세포대TRAIL적내수한제료기엄범응용우림상.수체여배체적결합시조망신호계동적기시급관건배절,인차종류세포발생TRAIL내수적궤제여수체적표체、정위、분포、공능등밀절상관.연합기타치료수단침대수체파점,실현개체화치료,유망최종극복종류세포적TRAIL내수.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) preferentially induces apoptosis in tumor cells but not in normal cells. It induces apoptosis in its target cells by interacting with surface death receptors DR4 and DR5,which contain a cytoplasmic region designated as the " death domain". Clinical use of rhTRAIL and its agonistic antibodies is limited due to partial or completetolerance to TRAIL in human tumor cell lines. As TRAIL binding to its death receptors is the initial and crucial step in initiating apoptosis, the mechanisms of TRAIL-tolerance in tumor cells is closely related to the expression,location,distribution and function of TRAIL receptors . Personalized care combined with other therapies targeting TRAIL receptors may be expected to overcome the TRAIL-tolerance of tumor cells eventually.